I am a board-certified medical oncologist who specializes in treating men with prostate cancer, particularly those who have metastatic disease (disease that has spread to distant organs) or who are at high risk of developing metastatic disease.
Much of my research bridges the fields of medical oncology and nuclear medicine. I am working with colleagues on Memorial Sloan Kettering’s Nuclear Medicine Service to develop radiopharmaceuticals — liquid drugs that deliver radiation therapy directly to cancer cells or to the areas in the skeleton that harbor prostate cancer cells. I am exploring one class of these drugs, called bone-seeking radiopharmaceuticals, in combination with chemotherapy. I am also exploring a new form of bone-seeking radiopharmaceutical that has fewer side effects in the bone marrow.
Another research interest is developing new ways to image prostate cancer in the bones using unique, prostate-cancer-specific PET scans and other new imaging modalities. This type of imaging not only provides an insight into where the prostate cancer is located, but informs us about its biology as well.
Finally, I am interested in finding ways to prevent metastatic disease in patients who have undergone prostatectomy but whose PSA is rising rapidly. I am leading an international study for these patients in which we hope to determine whether early and aggressive treatment can delay, if not prevent, the development of metastases.
One of my priorities is increasing patient access to clinical trials. I am currently involved in the development of the Prostate Cancer Clinical Trials Consortium (PCCTC), an initiative designed to increase patient access to clinical trials across the country. I also sit on Cancer and Leukemia Group B (CALGB)’s genitourinary committee, a National Cancer Institute-designated group composed of local and academic oncology centers, to facilitate clinical testing of new drugs throughout the country. In addition, I am very involved with the American Society of Clinical Oncology (ASCO); I am on ASCO’s Education Committee and chair of the Genitourinary Scientific Track.
- Clinical Expertise: Prostate Cancer; New Investigational Agents
- Languages Spoken: English
- Education: MD, Mount Sinai School of Medicine
- Residencies: Columbia-Presbyterian Medical Center
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Michael J. Morris
- A Phase I Study of EC1169 in Men with Recurrent Metastatic Castration-Resistant Prostate Cancer
- A Phase II Study of Abiraterone Acetate without Simultaneous Prednisone in Men with Castration-Resistant Prostate Cancer, with Hormonal Assessment During Treatment
- A Phase III Study of Enzalutamide Alone or with Abiraterone and Prednisone for Metastatic Castration-Resistant Prostate Cancer
- [18F]-Deoxy-D-Glucose (FDG) and [18F] Dihydro-Testosterone PET Imaging in Patients with Progressive Prostate Cancer
Clinical Trials Co-Investigated by Michael J. Morris
- A Phase II Study of Abiraterone, Prednisone, and Degarelix in Men with Recurrent Prostate Cancer and a Rising PSA
- A Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
- A Study of [18F] Dihydro-testosterone PET and MR Imaging in Patients with Localized Prostate Cancer
- The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men with Prostate Cancer Age 65 and Older